About Mitochondrial import inner membrane translocase subunit TIM50
Mitochondrial import inner membrane translocase subunit TIM50 (TIMM50) is a protein
from Homo sapiens identified by UniProt accession
Q3ZCQ8, 353 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Mitochondrial import inner membrane translocase subunit TIM50 |
| UniProt accession | Q3ZCQ8 |
| Gene | TIMM50 |
| Organism | Homo sapiens |
| Length | 353 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (42)
Diseases linked to this target (Open Targets).
- 3-methylglutaconic aciduria type 9 · score 0.77
- neurodegenerative disease · score 0.52
- Mitochondrial encephalopathy · score 0.43
- genetic disorder · score 0.41
- Epileptic encephalopathy · score 0.37
- neutrophil count · score 0.11
- leukocyte count · score 0.11
- myeloid white cell count · score 0.06
- cardiac hypertrophy · score 0.06
- neoplasm · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q3ZCQ8-F1 | alphafold | PREDICTED | 79.85 | — |
Amino-acid sequence (353 residues)
MAASAAVFSR LRSGLRLGSR GLCTRLATPP RRAPDQAAEI GSRGSTKAQG PQQQPGSEGP SYAKKVALWL AGLLGAGGTV SVVYIFGNNP VDENGAKIPD EFDNDPILVQ QLRRTYKYFK DYRQMIIEPT SPCLLPDPLQ EPYYQPPYTL VLELTGVLLH PEWSLATGWR FKKRPGIETL FQQLAPLYEI VIFTSETGMT AFPLIDSVDP HGFISYRLFR DATRYMDGHH VKDISCLNRD PARVVVVDCK KEAFRLQPYN GVALRPWDGN SDDRVLLDLS AFLKTIALNG VEDVRTVLEH YALEDDPLAA FKQRQSRLEQ EEQQRLAELS KSNKQNLFLG SLTSRLWPRS KQP
Explore Mitochondrial import inner membrane translocase subunit TIM50 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets